ISACA Releases New Report on Privacy Trends, Obstacles and Predictions Ahead of Data Privacy Day
26.1.2021 19:16:00 EET | Business Wire | Press release
As Data Privacy Day approaches this week, ISACA has released a new survey report, Privacy in Practice 2021: Data Privacy Trends, Forecasts and Challenges, exploring past and future trends in privacy by design, privacy obstacles and privacy workforce.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005846/en/
The current privacy landscape is rife with low investment, lack of high-level prioritization and lack of skilled privacy professionals that leave organizations open to penalties and loss of reputation. ISACA, a global professional association and learning organization, surveyed more than 1,800 IT audit, risk, security and privacy professionals on privacy workforce trends and skills gaps, privacy programs, and the regulations and frameworks that guide privacy programs. (Graphic: Business Wire)
Privacy by Design
Enterprises that report they always use privacy by design are more likely to be driven by a combination of compliance and ethics (62 percent vs. 52 percent total). They are also nearly two-and-a-half times more likely to be completely confident in their privacy team’s ability to ensure data privacy and achieve compliance with new privacy laws and regulations (24 percent vs. 10 percent total). However, there was not a meaningful difference in the number of privacy breaches they experienced in the last 12 months compared to all respondents. Approximately 10 percent of both groups reported breaches—a potentially underreported number.
Privacy Obstacles
Respondents identified other common privacy failures, including:
- Lack of training or poor training (64 percent)
- Failure to perform a risk analysis (53 percent)
- Bad or nonexistent detection of personal information (50 percent)
Respondents cited privacy principles frameworks, experience-based credentials and privacy training as the most helpful methods in overcoming these obstacles.
Workforce Trends
Respondents indicated that they foresee an increased demand for technical privacy roles compared to legal/compliance roles (70 percent increase vs. 59 percent increase). However, technical privacy roles were more likely to be considered understaffed (46 percent vs. 33 percent).
Nevertheless, hiring managers have been filling these roles through training—47 percent noted they have been training non-privacy staff interested in moving into privacy roles. Ninety-two percent of respondents indicated that they have privacy staff who started their career in IT or security and moved into privacy and compliance.
“Organizations will continue needing a strong privacy workforce in the years ahead,” says Nader Qaimari, ISACA chief product officer. “As non-privacy professionals increasingly get opportunities to train for this career path and gain technical skills, it not only eases the privacy skills gap but enriches this workforce.”
The complimentary webinar, “Exploring Privacy Trends, Challenges & Predictions,” on 28 January 2021 at 12:00 PM EST / 5:00 PM (UTC) will explore the survey highlights. To learn more, visit www.isaca.org/education/online-events/lms_w012821.
Access the Privacy in Practice 2021 survey report at www.isaca.org/privacy-in-practice-2021. Learn more about ISACA’s privacy resources, including the Certified Data Privacy Solutions Engineer™ (CDPSE™) certification, at www.isaca.org/cdpse.
About ISACA
For more than 50 years, ISACA® (www.isaca.org) has equipped individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enables enterprises to train and build quality teams. ISACA leverages the expertise of more than 150,000 members who work in information security, governance, assurance, risk and privacy to drive innovation through technology. Its presence in 188 countries includes more than 220 chapters.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005846/en/
Contact information
Emily Van Camp, +1.847.385.7217, communications@isaca.org
Kristen Kessinger, +1.847.660.5512, kkessinger@isaca.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
